Marker Therapeutics, Inc. (MRKR)
| Market Cap | 23.68M |
| Revenue (ttm) | 3.55M |
| Net Income (ttm) | -12.16M |
| Shares Out | 16.67M |
| EPS (ttm) | -0.79 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 79,497 |
| Open | 1.460 |
| Previous Close | 1.450 |
| Day's Range | 1.400 - 1.489 |
| 52-Week Range | 0.810 - 4.070 |
| Beta | 1.47 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+604.23%) |
| Earnings Date | May 14, 2026 |
About MRKR
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreat... [Read more]
Financial Performance
In 2025, Marker Therapeutics's revenue was $3.55 million, a decrease of -46.19% compared to the previous year's $6.59 million. Losses were -$12.16 million, 13.3% more than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for MRKR stock is "Strong Buy" and the 12-month stock price target is $10.0.
News
Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results
Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses
Marker Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The MAR-T platform offers a first-in-class, multi-antigen T-cell therapy with strong safety and efficacy in lymphoma, showing high response rates and durable outcomes in heavily pretreated patients. Expansion into solid tumors and off-the-shelf products is underway, supported by significant non-dilutive funding.
Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...
Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study
Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment
Marker Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Multi-TAA T-cell therapy shows promise in DLBCL and solid tumors, with strong safety and efficacy in heavily pretreated patients. Manufacturing is streamlined, and pivotal trials are planned for early next year, with off-the-shelf and solid tumor programs advancing.
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...
Marker Therapeutics Stock Drops After Report About Lymphoma Treatment
Marker Therapeutics, Inc. MRKR on Tuesday provided an update on the progress and clinical observations from the Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell prod...
Marker Therapeutics Transcript: Study Update
MT-601 demonstrated a 50% complete response rate and 66% overall response rate in heavily pretreated non-Hodgkin lymphoma patients, with durable responses and an excellent safety profile, even at the highest tested dose. The therapy addresses significant unmet needs in relapsed/refractory lymphoma, especially after CAR T and bispecific antibody failures.
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating...
Marker Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference
MAR-T cell therapy targets multiple tumor antigens without genetic modification, showing strong response rates and a favorable safety profile in lymphoma. The lead asset MT-601 is advancing in both hematologic and solid tumors, supported by robust manufacturing and government funding.
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive...
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025 Virtual event with Key Opinion Leaders to discuss cell therapy landsca...
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for t...
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, inc...
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...
Marker Therapeutics Announces $16.1 Million Private Placement
Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells Strategic financing supports clinical ...
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR)
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th...